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The effect of gabapentin on cognition and quality of life (QoL) in patients with epilepsy was investigated using a controlled 
pre- and post-treatment design. Thirty patients with chronic epilepsy were administered abattery of cognitive tests and QoL 
measures atbaseline (pre-treatment) and again following l-2 months of treatment (post-treatment). All patients were receiving 
anticonvulsant medication at baseline. Following baseline assessment, 15patients were started on gabapentin as add-on therapy 
(gabapentin group), and 15 patients remained on stable medication (control group). No between-group treatment effects were 
demonstrated on any of the mood measures. A significant between-group treatment effect was demonstrated on one cognitive 
measure, in favour of the gabapentin group. Results do not suggest any adverse short-term effects of gabapentin on cognition or 
QoL in patients with chronic epilepsy. 
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INTRODUCTION 
The influence of anticonvulsant drugs on cognitive 
function has been an important area of research inter- 
est in recent years. Most studies have been carried out 
on the standard treatments, notably phenobarbitone, 
phenytoin, and carbamazepine. While there has been 
some debate as to the differences between these’v2, 
there seems to be agreement that all of this generation 
of drugs affects cognition in some way. The search for 
treatments with minimal adverse effects was important 
in stimulating an interest in cognition in epilepsy, and in 
raising the relevance of cognitive side effects of drugs 
for quality of life (QoL) in epilepsy3. 
The recent years have seen the introduction of several 
new anticonvulsants into clinical practice. Disappoint- 
ingly, with the exception of vigabatrin4y5, there has 
been little attempt to assess the effects of these drugs 
on cognition. In this study we present the results of 
an add-on study with gabapentin, in which effects on 
cognition and QoL have been measured. 
MATERIALS AND METHODS 
Participants 
Thirty outpatients with chronic epilepsy, attending the 
National Hospital for Neurology and Neurosurgery, 
London, took part in the study. Patients were invited 
to participate if they were 18 years of age or over, and 
were either to begin gabapentin as add-on therapy, or 
to remain on a stable drug regime. Patients were not as- 
signed randomly to groups, but on clinical grounds. Pa- 
tients with moderate to severe learning disability were 
not included in the study due to constraints imposed 
by task requirements. Patients who might be classi- 
fied as having learning difficulties or a mild learning 
disability were included in the study, so representing 
patients who might experience difficulty with learning 
secondary to epilepsy-related variables (e.g. brain dam- 
age, seizure frequency, medication). Written informed 
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consent was obtained from all participating patients. 
Blood was taken for assessment of gabapentin levels as 
soon as possible after cognitive testing was performed. 
Cognitive measures 
Critical Flicker Fusion (CFF)6 
The Critical Flicker Fusion (CFF) task was developed 
to measure ‘central integrative ability’ and has been 
shown to be sensitive to both sedative and stimulant 
drug effects. 
The CFF is presented using the Leeds Psychomotor 
Tester. The Tester contains four light-emitting diodes 
(LEDs) which flicker at either an increasing rate (the 
‘Up’ condition) or a decreasing rate (the ‘Down’ con- 
dition). On each trial, participants are asked to focus 
on a set of four lights. In the ‘Up’ condition, the lights 
appear to be flickering at the start of each trial, and par- 
ticipants are asked to press a switch as soon as the lights 
appear to stop flickering. In the ‘Down’ condition, the 
lights appear to be still at the start of each trial, and par- 
ticipants are asked to press the same switch as soon as 
the lights appear to start flickering. Two 6-trial blocks 
are administered for each condition, and conditions al- 
ternate between blocks. The Leeds Psychomotor Tester 
records the flicker-detection threshold (cycles per sec- 
ond) for each trial. The mean flicker-detection thresh- 
old of all 24 trials (collapsed across the two conditions) 
is taken as the measure of performance. 
Verbal Memory (VM; Evans. Thompson, personal 
communication) 
The Verbal Memory task measures recognition and re- 
call (immediate and delayed) of newly learned verbal 
material, and is comparable to the Rey Auditory Verbal 
Learning test’. Separate stimulus sets are used at pre- 
and post-treatment assessment. This task was used in 
this study to yield four measures of verbal memory per- 
formance. For all four measures, false-negative but not 
false-positive errors were accounted for by the measure 
of performance. 
Immediate recall. A list of 12 words was read aloud to 
participants at a rate of one word per second. Partic- 
ipants were then asked to recall as many words from 
the list as they could (in any order). The number of cor- 
rectly recalled words (/12) on this first trial was taken 
as the measure of immediate recall. 
Best recall. The above procedure was repeated until 
participants had either correctly recalled all 12 words, 
or the maximum of eight trials had been administered. 
The highest number of correctly recalled words (/12) 
achieved on any trial was taken as the measure of best 
recall. 
Recognition. Participants were then given a list of 60 
written words, arranged in three columns of 20 words 
each. The list included the 12 previously presented tar- 
get words scattered among 48 new distractor words. 
Participants were asked to identify the previously pre- 
sented target words. The number of correctly recog- 
nized words (/12) was taken as the measure of recog- 
nition. 
Delayed recall. Approximately 1 hour following the 
immediate recall task, participants were asked to recall 
as many of the 12 target words as they could. The num- 
ber of correctly recalled words (/12) was taken as the 
measure of delayed recall. 
Paced Auditory Serial Addition Task (PASAT) 
The Paced Auditory Serial Addition Task (PASAT) 
measures attention and concentration, working mem- 
ory and mental flexibility, and also requires simple 
mental arithmetic and mental speed. 
Four lists, each of 50 single-digit numbers, are pre- 
sented aurally with a tape-recorder. The pace, or rate 
of presentation of numbers, increases with each suc- 
cessive list (one number every 2.4, 2.0, 1.6, and 1.2 
seconds, respectively). For each list, participants are 
asked to add each number to the preceding number, 
and then to say the sum aloud, before the subsequent 
number is presented (e.g. ‘11, 10, 7.: in response to 
the numbers ‘3, 8, 2, 5..‘). For this study, the first list 
(2.4 seconds) was used as a practice trial. The number 
of correct additions (/49) for each of the three remain- 
ing lists (2.0, 1.6 and 1.2 seconds) were taken as the 
measures of performance. 
Stroop Neuropsychological Screening Test (SNST)g 
The standard Stroop interference task is widely used 
as a measure of attention, but also measures prepo- 
tent inhibition and thus is an aspect of executive func- 
tion. Trenerry and colleagues’ version of the standard 
Stroop task (the Stroop Neuropsychological Screening 
Test; SNST) is recommended for use with adults from 
18 years of age, with the usual conditions that partic- 
ipants must be fluent readers of English, and have no 
(uncorrected) visual impairment of acuity or colour vi- 
sion. 
The SNST has two conditions. In each condition, 
participants are presented with a list of 112 stimulus 
items arranged in four columns each of 28 items. Each 
item is a colour-word printed in a conflicting coloured 
ink (e.g. the colour-word ‘RED’, printed in blue ink). 
In the first condition, participants are instructed to read 
aloud the colour-words (word-reading), and in the sec- 
ond condition, participants are instructed to name aloud 
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the ink-colour in which the words are printed (colour- 
naming). In both conditions, participants are asked to 
respond as quickly and as accurately as they can. For 
each condition, the number of correct responses (/112) 
achieved within 2 minutes is taken as the measure of 
performance. Correct responses include errors which 
are spontaneously corrected, as the time taken to correct 
the error is necessarily accounted for by the dependent 
measures. 
Quality of life (QoL) measures 
General Health Questionnaire-30 (GHQ-30)‘O 
The General Health Questionnaire (GHQ) is a self- 
rating questionnaire designed as a screening instrument 
for psychiatric case identification, with a focus on psy- 
chological components of ill-health. The GHQ mea- 
sures breaks in normal function (i.e. inability to con- 
tinue normal healthy functions, and the appearance of 
new distressing phenomena) rather than lifelong traits, 
and so is sensitive to transient disturbance. Although 
designed to discriminate between predicted cases and 
non-cases, the GHQ can also be used as a dimensional 
measure of psychological disturbance. The abbreviated 
GHQ-30 was selected among the various versions of 
the GHQ, as it is recommended for use with patients 
with physical illness. The Likert (O-l-2-3) scoring sys- 
tem was used to measure the degree of psychological 
disturbance, to maximize sensitivity to change. The de- 
pendent measure is a total score (/90), which reflects 
the degree of self-rated disturbance. 
Epilepsy Surgery Inventory-55 (ESI-55)’ ’ 
The Epilepsy Surgery Inventory-55 (ESI-5.5) is a 55- 
item measure of health-related QoL, designed to as- 
sess the effects of surgery on patients with epilepsy. 
The ESI-55 can also be used to assess the effects of 
anticonvulsant medication on patients with epilepsy. 
Three composite scores (/lOO) can be calculated, higher 
scores indicating a higher QoL. These composite 
scores, mental health, physical health, and role func- 
tioning, were used as the dependent measures for this 
study. 
Procedure 
Patients were tested individually at the Institute of Neu- 
rology. For baseline assessment, patients were seen fol- 
lowing an outpatient clinic appointment. All patients 
were scheduled to be seen again l-2 months later for 
post-treatment assessment. Following baseline assess- 
ment, patients in the gabapentin group were started on 
a dose of 400 mg gabapentin, increasing by 400 mg 
weekly over 4 weeks to reach a target dose of 1600 mg 
(i.e. weeks 14: 400,800,1200,1600 mg, respectively). 
For both pre- and post-treatment assessment, he cogni- 
tive battery was administered before the QoL measures. 
The cognitive tests were administered in the following 
order: VM (Immediate Recall, Best Recall, Recogni- 
tion), CFF, SNST, PASAT, VM (Delayed Recall). The 
GHQ-30 followed by the ESI-55 were administered at 
the end of each testing session. 
RESULTS 
Patients in the gabapentin group were aged between 
24:3 and 71:3 (years:months), with a mean of 39:9 
(SD = 14: 5). The gabapentin group consisted of six 
males and nine females, giving a sex ratio of 1: 1.5 
(male:female). Patients in the control group were aged 
between 21:8 and 61:6, with a mean age of 37:2 
(SD = 11: 1). The control group consisted of eight 
males and seven females, giving a sex ratio of 1.1: 1 
(male:female). No significant between-group differ- 
ences were found for age or sex (Age: two-tailed inde- 
pendent samples r-test, t(28) = 0.56; Sex: two-tailed 
Pearson, chi-square; chi( 1) = 0.54; both p > 0.05). 
Baseline clinical details for each patient group are 
shown in Tables 1 and 2. For the gabapentin group, 
post-treatment gabapentin dosages ranged from 800- 
1600mg,withameanof 1428.6(SD = 302.4;n = 14). 
Blood serum levels for gabapentin were available for 
nine of the gabapentin patients. Among these patients, 
post-treatment serum levels ranged from 5 to 62, with 
a mean of 29.9 (SD = 19.1). 
Cognitive measures 
Mean pre- and post-treatment scores on cognitive mea- 
sures for the gabapentin and control groups are shown 
in Table 3. 
Between-group two-tailed independent samples f- 
tests were performed on difference scores (post- mi- 
nus pre-treatment). A significant difference was found 
on the word-reading condition of the SNST (t(26) = 
2.26, p <: 0.05), in favour of the gabapentin group. 
No significant differences were found for any of the 
remaining cognitive measures (CFF: r(28) = 0.80; 
VM Immediate Recall: t(28) = 0.39; VM Best Re- 
call: t (28) = 0.45; VM Delayed Recall: t (28) = 0.74; 
VM Recognition: t (28) = 1.03; PASAT 2.0s: follow- 
ing Levene’s test for homogeneity of variances, ad- 
justed r( 19.0) = 0.65; PASAT 1.6s r(27) = 0.93; 
PASAT 1.2s t(27) = 0.71; SNST colour-naming 
t(26) = 0.27; all p > 0.05). Between-group com- 
parisons are shown in Table 3. 
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Within-group two-tailed paired samples f-tests were 
also performed to test for differences on cognitive mea- 
sures between pre- and post-treatment, for each group 
respectively. For the gabapentin group, significant im- 
provement was found on all PASAT measures and both 
SNST measures (PASAT 2.0s: t (14) = 2.50; PASAT 
1.6s t(14) = 2.32; PASAT 1.2s: t(14) = 2.48; SNST 
word-reading t(13) = 2.28; SNST colour-naming 
t (13) = 2.48; all p .c 0.05). For the control group, sig- 
nificant improvement was found on the least demand- 
ing PASAT measure only (PASAT 2.0s: f (13) = 4.15, 
p < 0.05). Within-group comparisons are shown in 
Table 3. 
For the gabapentin group, two-tailed Spearman’s cor- 
relations were performed between gabapentin serum 
levels and cognitive difference scores. Gabapentin 
serum level was significantly positively correlated with 
VM Delayed Recall (r(9) = 0.70, p = 0.036), but not 
with any of the remaining cognitive measures. 
Quality of life (QoL) measures 
Mean pre- and post-treatment scores on the GHQ-30 
and the ESI-55 for the gabapentin and control groups 
are shown in Table 4. 
Between-group two-tailed independent samples t- 
tests were performed on difference scores (post- mi- 
nus pre-treatment). No significant difference was found 
on the GHQ30 (t(28) = 0.52, p > 0.05) or on 
any of the ESI-55 composite score (Mental Health: 
t(28) = 0.16; Physical Health: t(28) = 0.45; Role 
Functioning: r(28) = 0.43; all p > 0.05). Between- 
group comparisons are shown in Table 4. 
Within-group two-tailed paired samples r-tests were 
performed to test for differences on QoL measures be- 
tween pre- and post-treatment, for each group respec- 
tively. For the gabapentin group, significant improve- 
ment was found on all ESI-55 composite scores (Mental 
Health: t (14) = 2.26; Physical Health: r (14) = 2.39; 
Role Functioning: t(14) = 2.36; all p < 0.05). For 
the control, significant improvement was found on 
two ESI-55 composite scores (Mental Health: t (14) = 
2.92; Role Functioning: t (14) = 2.23; both p -c 0.05). 
Within-group comparisons are shown in Table 4. 
For the gabapentin group, two-tailed Spearman’s cor- 
relations were performed between gabapentin serum 
levels and QoL difference scores. No significant cor- 
relations were found between gabapentin serum level 
and any of the QoL measures. 
Seizure frequency 
No significant between-group difference was found 
for baseline seizure frequency (two-tailed indepen- 
Table 1: Frequencies of diagnosis, seizure type, and 
medication status for the gabapentin and control groups at 
baseline. 
Gabapentin group Control group 
(n = 15) (n = 15) 
Diaenosis 
l&al epilepsy 15 12 
Generalized epilepsy 0 3 
Seizure type 
CPS” with 2” generalization 14 12 
CPS” without 2’ generalization 1 0 
I0 generalized seizures 0 1 
2’ generalized seizures 0 2 
Medication 
Monotherapyb I 5 
Polytherap? 
a Complex partial seizures. 
8 10 
b Gabapentin group: carbamazepine (cbz) n = 5, phenytoin (pht) 
n = 2; Control group: cbz n = 3, sodium valproate (sv) n = I, pht 
n = I. 
’ Gabapentin group: cbz + pht n = 2, cbz + sv + clobazam 
II = I, cbz + cbz epoxide + lamotrigine (Itg) + clobazamn = 1, 
oxcarbazepine + IO-hydroxycarbazepine + clobazam n = I, sv + 
clobazam n = I, pht + phenobarbitone (phb) n = 1, phb + 
primidone n = I; Control group: cbz + Itg n = 1, cbz + vigabatrin 
n = I, cbz + vigabatin + clobazam n = 1. sv -I- pht n = 2, sv f 
Itg n = 1, sv + vigabatrin n = 1, pht + ethosuximide n = 1, pht + 
Itg + clobazam n = 1, pht + phb + primidone n = 1. 
Table 2: Mean age at onset and duration of epilepsy, and 
mean seizure frequency for the gabapentin and control 
groups at baseline. 
Gabapentin group Control group 
(n = 15) (n = 15) 
Age at onset (yrs:mos) 13:6(11:9) 15:0(13:1) 
Duration (yrs:mos) 25:10(11:0) 21:6 (11:2) 
Seizure frequency (/mo) 10.3 (9.50)a 5.87 (9.24) 
‘n = 12. 
dent samples r-test, f (25) = 1.21, p > 0.05), or 
for seizure frequency difference scores (post- minus 
pre-treatment; two-tailed independent samples r-test, 
t(25) = 0.25,~ > 0.05). 
DISCUSSION 
In this study we have assessed the effects of adding 
on gabapentin to the existing therapy of patients with 
intractable epilepsy, receiving the drug in a clinical 
setting. Ideally, we would have conducted a placebo- 
controlled study, with monotherapy, but ethical con- 
straints do not allow such a design. We have therefore 
followed a design we have used previously, especially 
testing a matched control group, that do not undergo 
any changes of therapy with the same protocol. This 
allows a control for the experimental setting, and for 
practice effects. 
The cognitive tests we used were similar to those we 
have used previously5, namely tests with minimal mo- 
tor components, as it has been suggested that much of 
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Table 3: Mean pre- and post-treatment scores on cognitive measures for the gabapentin and control groups. 
CFP 
Gabapentin group (n = 15) 
Pre-treatment Post-treatment pa 
23.8 (2.47) 24.0 (2.85) NS 
- - 
Control group (n = 15) 
Pre-treatment Post-treatment pa 
24.6 (2.73) 25.3 (2.93) NS 
VM Immediate 
Recall (112) 
VM Best Recall (112) 
VM Delayed Recall (/12) 
VM Recognition (112) 
PASAT 2.0s (/49) 
PASAT 1.6s (/49) 
PASAT 1.2s (/49) 
SNST Word- 
reading (II 12) 
SNST Colour- 
naming (II 12) 
5.27 (I .33) 
10.7 (1.40) 
7.53 (2.17) 
I 1.5 (0.83) 
26.9 (10.8) 
24.0 (8.15) 
18.5 (8.47) 
11 1.6 (0.63)’ 
91.6 (21.7)’ 
5.47 (1.64) 
10.9 (1.10) 
7.53 (2.17) 
11.7 (0.62) 
32.3 (13.6) 
28.2 (10.5) 
23.4 (8.89) 
119.9 (0.27)c 
96.3 (20.6Y 
NS 
NS 
NS 
NS 
p = 0.026 
p = 0.036 
p = 0.027 
p = 0.040 
I) = 0.028 
5.47 (1.92) 
10.9 (0.99). 
8.07 (3.47) 
11.5 (0.83) 
28.6 (7.80)c 
25.7 (8.02)’ 
20.3 (7.49)c 
119.9 (0.27)c 
100.0 ( 11 .O)C 
5.93 (1.28) 
11.3(1.03) 
8.47 (3.25) 
11.3 (0.90) 
32.5 (9.25)’ 
27.8 (9.44)c 
23.4 (8.03)c 
1 11.8 (0.43)c 
103.8 (12.7F 
NS NS 
NS NS 
NS NS 
NS NS 
p =O.OOl NS 
NS NS 
NS NS 
NS p = 0.03 
NS NS -. ., . . , . , 
a Within-group two-tailed paired samples f-tests comparing pre- and post-treatment. 
b Between-group two-tailed independent samples r-tests on difference scores (post- minus pre-treatment). 
c ,* = 14. 
Table 4: Mean pre- and post-treatment scores on quality of life measures for the gabapentin and control groups. 
Gabapentin group (n = 15) Control group (n = 15) 
Pre-treatment Post-treatment pa Pre-treatment Post-treatment pa Pb 
GHQ-30 (/90) 39.8 (15.1) 29.9 (13.6) NS 34.9 (15.3) 28.5 (12.5) NS NS 
ESI-55 Composites (1100) 
Mental health 51.0(13.6) 59.7 (15.9) p = 0.040 55.7 (20.5) 65.2 (16.0) p=O.Oll NS 
Physical health 57.7 (19.6) 66.9 (16.5) p = 0.031 65.4 (23.9) 72.2 (21.8) NS NS 
Role functioning 5 1.6 (22.4) 66.7 (23.4) p = 0.033 58.5 (35.3) 70.1 (28.4) p =0.043 NS 
a Within-group two-tailed paired samples r-tests comparing pre- and post-treatment. 
b Between-group two-tailed independent samples r-tests on difference scores (post- minus pre-treatment). 
the effect of these drugs on cognitive function relates to 
motor slowing. We have always been more interested 
in effects on higher cognitive, as opposed to psychomo- 
tor, function. In this study we also included assessment 
of QoL. 
Measuring QoL is still in its relative infancy com- 
pared with cognition, and there are few studies on 
the effects of anticonvulsants on such measures. We 
chose the ESI-55 as it has been used in several recent 
studies’ ‘, and has been shown to have reliable clinimet- 
tics, including responsiveness, to surgical intervention 
at least. As psychopathology, especially depression, is 
an important component of QoL, we also included the 
GHQ. 
The most import@ conclusion from the data reflects 
on the lack of an observable negative influence on ei- 
ther cognition or QoL from the addition of gabapentin. 
There are significant improvements in both groups 
in cognitive function, and the profile (Table 3) im- 
plies more widespread improvements in the gabapentin 
group, compared with the comparison group. While we 
would not overemphasize the significance of this from 
this study, with its design, these data add to and sub- 
stantiate other cognitive studies with gabapentin. 
Leach et a112, using a double-blind design, gave a 
battery of psychomotor and memory tests to patients, 
and examined the effect of different doses. They found 
no effects of the active drug. 
Arnett et alI3 used a cognitive battery of 19 vari- 
ables and a QoL questionnaire to assess the effects of 
gabapentin in a large double-blind study of intractable 
patients, and included a group (n = 106) on monother- 
apy with the drug. Patients on polytherapy or monother- 
apy showed significant improvements, notably with 
faster perceptual and motor performance on the drug. 
Finally, although again with small numbers, we 
did note a significant correlation between one of our 
cognitive measures and a change of serum level of 
gabapentin. While this may have been a chance re- 
sult from a type-2 error, such pharrnacodynamic- 
pharmacokinetic relationships may be relevant to the 
interpretation of the overall results. 
With regards to measures of QoL, Leach et alI2 gave 
the SEALS, a questionnaire designed essentially to de- 
tect drug side effects, rather than QoLperse. No effects 
were noted over the 12 weeks of the study. In the study 
of Amett etal13, improvements on the Washington Psy- 
chosocial Inventory (WPSI) were reported, especially 
for the subscales of personal and interpersonal adjust- 
ment. Dimond et al’” also assessed the possible influ- 
ence of gabapentin on mood and general well-being in 
194 patients from an overall 423 patients taken from 
five double-blind trials with the drug. Global assess- 
ments and Activities of Daily Living were evaluated, 
but not in a good systematic way. There were sugges- 
tions that patients reported improved QoL, irrespec- 
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tive of control of seizures, and especially at higher 
doses (1800 mg). These data hinted that gabapentin 
may have, like some other anticonvulsants’5, an inde- 
pendent effect on mood. Recent anecdotal reports of 
its effect as a mood stabilizer in bipolar affective disor- 
der supports this suggestion16, but further studies are 
needed. Our own data are inconclusive, the only dif- 
ference between the groups being on physical health, 
significant only in the gabapentin group. This was not 
associated with control of seizures (correlations be- 
tween change of seizures and this variable not being 
significant). However, the timescale of our study was 
too short to make many comments regarding the influ- 
ence of gabapentin on QoL. We will complement these 
data soon with longer term QoL follow-up data. From 
this study we emphasize only the lack of any adverse 
influence. 
It is interesting to note the improvements in QoL 
scores in the comparison group. This either reflects 
on the clinimetric properties of the ESI-55, suggesting 
lack of reliability over time, or the influence of simply 
taking patients such as these into a study and carrying 
out cognitive and QoL tasks. We are inclined to sus- 
pect the latter, which in part explains the well-observed 
placebo effect of anticonvulsants in placebo-controlled 
clinical trials. 
We conclude that the addition of gabapentin to in- 
tractable patients with epilepsy as polytherapy in the 
dose range we have given has no detectable adverse 
influences on cognitive function or QoL, and the data 
suggest, if anything, some positive influences. While 
we cannot conclude the latter definitively from our de- 
sign, these data are in keeping with the few other studies 
with this drug that have been reported. Clearly, further 
work on the influence of gabapentin on mood and QoL 
would be of value. 
ACKNOWLEDGEMENTS 
We would like to thank the patients who took part in 
this study for their co-operation. 
C. Mortimore et a/ 
REFERENCES 
I. 
2. 
3. 
4. 
5. 
6. 
I. 
8. 
9. 
10. 
1 I. 
12. 
13. 
14. 
15. 
16. 
Thompson, PJ. and Trimble, M.R. Neuropsychological aspects 
of epilepsy. In: Neuropsychotogical Assessment of Neumpsy- 
chiatricDisorders. 2nd Edition (Eds I. Grant and K.M. Adams). 
New York, Oxford University Press, 1996: pp. 263-287. 
Trimble, M.R. Anticonvulsant drugs and cognitive function: a 
review of the literature. Epilepsia 1987: 28 (Suppl. 3): 37-45. 
Trimble, M.R. Quality of life and cognitive function. In: 
Epilepsy and Qua/i/y of Life. (Eds M.R. Trimble and W.E. Dod- 
son). New York. Raven Press, 1994: pp. 183-198. 
Dijkstra, J.B., McGuire. A.M. and Trimble, M.R. The effect 
of vigabatrin on cognitive function and mood. Human Psy- 
chophannacology 1992; 7: 3 19-323. 
Thomas, L. and Trimble, M.R. The effects of vigabatrin on 
attention, concentration and mood: an investigation in healthy 
volunteers. Seizure 1996; 5: 205-208. 
Hindmarch, I. Critical Flicker Fusion frequency (CFF): the ef- 
fects of psychotropic compounds. Phannacopsychiaf~ 1982; 
15 (Suppl. I): 44-48. 
Rey, A. In: Neumpsychological Assessmenr. 3rd Edition (Ed. 
M. Lezak). Oxford University Press, 1995. 
Gronwall, D.M.A. Paced serial-addition task: a measure of re- 
covery from concussion. Perceprrtnl & Motor Skills 1977; 44: 
365-373. 
Trenerry, M.R., Crosson, B., DeBoe. J. and Leber, W.R. Slmop 
NertropsychologicalScreening Test Manual. Psychological As- 
sessment Resources. 1989. 
Goldberg, D. and Williams, P. A User’s Guide ro the Genera/ 
Health Quesrionnaire. NFER-Nelson, 1988. 
Vickrey, B.G., Hays, R.D., Graber, J., Rausch, R., Engle, J. and 
Brook, R.H. A health-related quality of life instrument for pa- 
tients evaluated for epilepsy surgery. Medical Care 1992; 30: 
299-3 19. 
Leach, JR, Girvan, J., Paul, A. and Brodie, M.J. Gabapentin 
and cognition: a double blind, dose ranging, placebo con- 
trolled study in refractory epilepsy. Journal of Neurology, Ncu- 
msurgeq Neumpsychiarv 1997; 62: 372-376. 
Amett, J.L., Dodrill, C.B., Garofalo, E.A., Hayes, A.G., 
Pierce, M.W. and Arbor, A. Neuropsychological, mood and 
psychosocial effects of gabapentin (in press). 
Dimond, K.R., Pande, A.C., LaMoreaux, L. and Pierce, M.W. 
Effect of gabapentin on mood and well being in patients with 
epilepsy. Progress in Neum-psychopharmacology and Biotog- 
icat Psychiatry 1996; 20: 407417. 
Trimble, M.R. Anticonvulsant drugs: mood and cognitive 
function. In: Epilepsy, Behaviour and Cognirive Function. 
(Eds M.R. Trimble and E.H. Reynolds). Chichester. Wiley, 
1988: pp. 135-144. 
Ryback, R.S., Brodsky, L. and Munasifi, F. Gabapentin in bipo- 
lar disorder. Journal of Neumpsychia:~ 1991; 9: 30 I. 
